ВЛИЯНИЕ СПИРАПРИЛА НА ДЛИТЕЛЬНОСТЬ МЕЖПРИСТУПНОГО ИНТЕРВАЛА ПРИ ПАРОКСИЗМАЛЬНОЙ МЕРЦАТЕЛЬНОЙ АРИТМИИ

Цель. Оценить влияние ингибитора ангиотензинпревращающего фермента спираприла на эффективность профилактической антиаритмической терапии больных с пароксизмальной мерцательной аритмией (МА).

Материал и методы. В открытое перекрестное исследование двух методов лечения с периодами полной отмены профилактической антиаритмической терапии было включено 40 пациентов с пароксизмальной МА. В течение 3 мес каждый больной получал комбинированную терапию (КТ) – профилактическую антиаритмическую терапию (ААТ) и спираприл в дозе 6 мг/сут (группа КТ) и только профилактическую ААТ (группа ААТ).

Результаты. Периоды до первого и второго пароксизма МА после отмены ААТ были сопоставимы в группах ААТ и КТ (p=0,4 и p=0,6 соответственно, критерий logrank).

Заключение. Использование спираприла в качестве вспомогательного средства при лечении больных с пароксизмальной МА в течение 3 мес не влияет на длительность межприступного интервала.

1. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:257-354.

2. Pedersen O.D., Bagger H., Kober L. et al. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100(4):376-380.

3. Vermes E., Tardif J.-C., Bourassa M.G. et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction. Insight from the Studies of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003;107(23):2926-2931.

4. Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Val￾sartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149(3):548- 557.

5. Ducharme A., Swedberg K., Pfeffer M.A. et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;151(5):985- 991.

6. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-719.

7. Van Noord T., Crijns H.J., van den Berg M.P. et al. Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Disord. 2005;5(1):3.

8. Ueng K.C., Tsai T.-P., Yu W.-C. et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of prospective and controlled study. Eur Heart J 2003;23:2090-2098.

9. Madrid A.H., Bueno M.G., Jose M.G. et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation 2002;106:331- 336.

10. Двойрин В.В., Клименков А.А. Методика контролируемых клинических испытаний. М.: Медицина, 1985.

11. Pritchett E.L.C., Hammill S.C., Reiter M.J. et al. Life-table methods for evaluating antiarrhythmic drug efficacy in patients with paroxysmal atrial tachycardia. Am J Cardiol 1983;52:1007-1012.

12. Weigl M., Gschwantler M., Gatterer E. et al. Reflux esophagitis in the pathogenesis of paroxysmal atrial fibrillation: results of a pilot study. South Med J. 2003;96(11):1128-1132.

13. Джахангиров Ф. В., Соколов С.Ф., Верхратский А.Н. Аллапинин – новый противоаритмический препарат растительного происхождения, Ташкент: Фан, 1993.

14. Tardif J.-C., Ducharme A., Guertin M.-C. et al. Angiotensin Converting Enzyme Inhibitors and Incidence of Atrial Fibrillation in Patient with Hypertension. AHA 2003 Abstracts on Disc, 2319.

15. Канорский С.Г., Скибицкий В.В., Выприцкая Е.А., Ремизова А.И. Сравнительная оценка влияния периндоприла на течение пароксизмальной фибрилляции предсердий у больных гипертонической болезнью и ишемической болезнью сердца. Кардиология 2000;(8):63-64.

16. Yin Y., Dallal D., Li Z. et al. Prospective randomized study comparing amiodaron vs. amiodaron plus losartan vs. amiodaron plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur Heart J 2006;27(15):1841-1846.

17. Opie Lionel H., Angiotensin-Converting Enzyme Inhibitors, Third Edition, University of Cape Town Press, 1999.

18. Guitard C., Alvisi V., Maibach E. et al. Placebo-controlled comparison of spirapril at 6, 12 and 24 mg/day in mild to severe essential hypertension. Blood Press Suppl. 1994;2:81-87.

19. Hayduk K., Schardt F., Sierakowski B. et al. Single daily administration of spirapril in the treatment of essential hypertension. A multicentre double-blind comparison of 1, 6, 12 and 24 mg of spirapril once daily. Blood Press Suppl. 1994;2:41-46.

20. N rgaard K., Jensen T., Christensen P., Feldt-Rasmussen B. A comparison of spirapril and isradipine in patients with diabetic nephropathy and hypertension. Blood Press. 1993;2(4):301-308.

21. Otterstad J.E., Froeland G. Changes in left ventricular dimensions and heamodynamics during antihypertensive treatment with spirapril for 36 months. Blood Press Suppl. 1994;2:69-72.

22. Waagshein F., Hjalmarson A., Varnauskas E. et al. Effect of chronic betaadrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;37:1022-1025.

23. Goette A., Arndt M., Rocken C. et al. Regulation of angiotesin II receptor subtype during atrial fibrillation in humans. Circulation 2000;101(23):2678-2681.

24. Brundel BJ, Van Gelder IC, Henning RH, et al. Ion channel remodeling is related to intraoperative atrial effective refractory periods in patients with paroxysmal and persistent atrial fibrillation. Circulation 2001;103(5):684-690.

25. Aime-Sempe C., Folliguet T., Rucker-Martin C. et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999;34(5):1577-1586.

26. Guiraudon C.M., Ernst N.M., Yee R. et al. The pathology of drug resistant lone atrial fibrillation in eleven surgically treated patients. In: Kingma J.H., Van Hernel N.M., Lie K.I. editors. Atrial Fibrillation: A Treatable Disease? Dordrecht: Kluwer Academic Pub, 1992. p.41-57.

27. Frustaci A., Chimenti C., Bellocci F. et al. Histological substrate of atrial biopsies in patients with lone atrial fibrillation. Circulation 1997;96: 1180-1184.

28. Aime-Sempe C., Folliguet T., Rucker-Martin C. et al. Myocardial cell death in fibrillating and dilated human right atria. J Am Coll Cardiol 1999;34(5):1577-1586.

29. van der Velden H.M., van Kempen M.J., Wijffels M.C. et al. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol 1998;9:596-607.

30. van der Velden H.M., Ausma J., Rook M.B. et al. Gap junctional remodeling in relation to stabilization of atrial fibrillation in the goat. Car￾diovasc Res 2000;46:476-486.

31. Wijffels M.C., Kirchhof C.J., Dorland R., Allessie M.A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented go￾ats. Circulation 1995;92(7):1954-1968.

32. Goette A., Honeycutt C., Langberg J.J. Elecrtical remodeling in atrial fibrillation: time course and mechanisms. Circulation 1996;94: 2968- 2974.

33. Ricard P., Levy S., Trigano J. et al. Prospective assessment of the minimum energy needed for external electrical cardioversion of atrial fibrillation. Am J Cardiol 1997;79:815-816.

34. Daoud E.G., Bogun F., Goyal R. et al. Effect of atrial fibrillation on atrial refractoriness in humans. Circulation 1996;94:1600-1606.

35. Shinagawa K., Shiroshita-Takeshita A., Schram G. et al. Effects of antiarrhythmic drugs on fibrillation in the remodeled atrium: insights into the mechanism of the superior efficacy of amiodaron. Circulation 2003;107:1440-1446.

36. Kochiadakis G.E., Igoumenidis N.E., Marketou M.E. et al. Low dose amiodarone and sotalol in the treatment of recurrent, symptomatic atrial fibrillation: a comparative, placebo controlled study. Heart 2000;84:251- 257.

37. Reimold S.C., Cantillon C.O., Friedman P.L., Antman E.M. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-563.

38. Chun S.H., Sager P.T., Stevenson W.G. et al. Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.

39. Roy D., Talajic M., Dorian P. et al. for the Canadian Trial of Atrial Fibrillation Investigators. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342:913-920.